Suven Life Sciences soared 5.89% to Rs 311.95 on reports the company will release the phase 2 data of its Alzheimer's drug, in a week.
The company's chairman & CEO Venkat Jasti told the media that the phase 2 data for SUVN 502, a drug for Alzheimer's disease, will be out in a week. No new drug to treat the mind-robbing disease has been discovered since 2003, Jasti reportedly added.
Meanwhile, the S&P BSE Sensex was down 211 points or 0.52% to 40,364.61.
The stock was trading in a range of Rs 292.35 to Rs 314.50 so far during the day. In the past one month, shares of Suven Life Sciences rose 8.71% to its current market price of Rs 311.95, outperforming the Nifty Pharma index's 3.99% rise in the same period.
Suven Life Sciences' consolidated net profit surged 1,535.90% to Rs 63.31 crore on 206.4% surge in net sales to Rs 274.31 crore in Q2 September 2019 over Q2 September 2018.
Suven Life Sciences is engaged in the business of manufacture and sale of bulk drugs and intermediaries.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.